183 related articles for article (PubMed ID: 35794532)
1. Molecular pathology testing for non-small cell lung cancer: an observational study of elements currently present in request forms and result reports and the opinion of different stakeholders.
Dufraing K; Van Casteren K; Breyne J; D'Haene N; Van Campenhout C; Vander Borght S; Zwaenepoel K; Rouleau E; Schuuring E; von der Thüsen J; Dequeker E
BMC Cancer; 2022 Jul; 22(1):736. PubMed ID: 35794532
[TBL] [Abstract][Full Text] [Related]
2. Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer.
Heitzer E; van den Broek D; Denis MG; Hofman P; Hubank M; Mouliere F; Paz-Ares L; Schuuring E; Sültmann H; Vainer G; Verstraaten E; de Visser L; Cortinovis D
ESMO Open; 2022 Apr; 7(2):100399. PubMed ID: 35202954
[TBL] [Abstract][Full Text] [Related]
3. Optimizing molecular testing of lung cancer needle biopsy specimens: potential solutions from an interdisciplinary qualitative study.
Fintelmann FJ; Martin NA; Tahir I; Quinn EM; Allen TC; Joseph L; Nikolic B; Lee C
Respir Res; 2023 Jan; 24(1):17. PubMed ID: 36650544
[TBL] [Abstract][Full Text] [Related]
4. Expert opinion on NSCLC small specimen biomarker testing - Part 2: Analysis, reporting, and quality assessment.
Penault-Llorca F; Kerr KM; Garrido P; Thunnissen E; Dequeker E; Normanno N; Patton SJ; Fairley J; Kapp J; de Ridder D; Ryška A; Moch H
Virchows Arch; 2022 Sep; 481(3):351-366. PubMed ID: 35857103
[TBL] [Abstract][Full Text] [Related]
5. Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non-Small-cell Lung Cancer: A Single-center Analysis.
Yu TM; Morrison C; Gold EJ; Tradonsky A; Layton AJ
Clin Lung Cancer; 2019 Jan; 20(1):20-29.e8. PubMed ID: 30243889
[TBL] [Abstract][Full Text] [Related]
6. Update on EGFR Mutational Testing and the Potential of Noninvasive Liquid Biopsy in Non-Small-cell Lung Cancer.
Kim E; Feldman R; Wistuba II
Clin Lung Cancer; 2018 Mar; 19(2):105-114. PubMed ID: 28935493
[TBL] [Abstract][Full Text] [Related]
7. Quality Assessment of Reporting Performance for
Han Y; Zhang R; Lin G; Zhang K; Xie J; Li J
Oncologist; 2017 Nov; 22(11):1325-1332. PubMed ID: 28701573
[TBL] [Abstract][Full Text] [Related]
8. CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer.
Prabhash K; Biswas B; Khurana S; Batra U; Biswas G; Advani SH; Mohapatra PN; Rajappa S; Sharma A; Patil S; Dattatreya PS; Roy R; Almel S; Goyal G; Warrier N
Indian J Cancer; 2022 Mar; 59(Supplement):S11-S18. PubMed ID: 35343188
[TBL] [Abstract][Full Text] [Related]
9. Clinical benefit and cost-effectiveness analysis of liquid biopsy application in patients with advanced non-small cell lung cancer (NSCLC): a modelling approach.
Englmeier F; Bleckmann A; Brückl W; Griesinger F; Fleitz A; Nagels K
J Cancer Res Clin Oncol; 2023 Apr; 149(4):1495-1511. PubMed ID: 35532791
[TBL] [Abstract][Full Text] [Related]
10. Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: A UK expert consensus statement.
Navani N; Butler R; Ibrahimo S; Verma A; Evans M; Doherty GJ; Ahmed S
Lung Cancer; 2022 Oct; 172():142-153. PubMed ID: 36099709
[TBL] [Abstract][Full Text] [Related]
11. Liquid biopsy for detection of EGFR T790M mutation in nonsmall cell lung cancer: An experience of proficiency testing in Taiwan.
Ho HL; Huang CC; Ku WH; Ho CL; Lin CH; Yu SL; Chou TY
J Chin Med Assoc; 2019 Jun; 82(6):473-476. PubMed ID: 30932938
[TBL] [Abstract][Full Text] [Related]
12. Translation of Knowledge to Practice-Improving Awareness in NSCLC Molecular Testing.
Zer A; Cutz JC; Sekhon H; Hwang DM; Sit C; Maganti M; Sung M; Binnie M; Brade A; Chung TB; Kamel-Reid S; Paul N; Tsao MS; Waddell T; da Cunha Santos G; Patel M; Carter RF; Leighl NB
J Thorac Oncol; 2018 Jul; 13(7):1004-1011. PubMed ID: 29535011
[TBL] [Abstract][Full Text] [Related]
13. The relevance of external quality assessment for molecular testing for ALK positive non-small cell lung cancer: results from two pilot rounds show room for optimization.
Tembuyser L; Tack V; Zwaenepoel K; Pauwels P; Miller K; Bubendorf L; Kerr K; Schuuring E; Thunnissen E; Dequeker EM
PLoS One; 2014; 9(11):e112159. PubMed ID: 25386659
[TBL] [Abstract][Full Text] [Related]
14. Causes behind error rates for predictive biomarker testing: the utility of sending post-EQA surveys.
Keppens C; Schuuring E; Dequeker EMC
Virchows Arch; 2021 May; 478(5):995-1006. PubMed ID: 33225398
[TBL] [Abstract][Full Text] [Related]
15. Cell-Free Circulating Tumour DNA Blood Testing to Detect
Ontario Health (Quality)
Ont Health Technol Assess Ser; 2020; 20(5):1-176. PubMed ID: 32206157
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of real-world data to determine clinical outcomes of patients with advanced non-small cell lung cancer following cell-free circulating tumor DNA genomic profiling.
Madison R; Schrock AB; Castellanos E; Gregg JP; Snider J; Ali SM; Miller VA; Singal G; Alexander BM; Venstrom JM; Chung JH
Lung Cancer; 2020 Oct; 148():69-78. PubMed ID: 32823229
[TBL] [Abstract][Full Text] [Related]
17. Implementing Genomic Testing for Lung Cancer Into Routine Clinical Practice - The Welsh Experience.
Cox S; Powell C; Morgan S
Clin Oncol (R Coll Radiol); 2022 Nov; 34(11):716-723. PubMed ID: 36088167
[TBL] [Abstract][Full Text] [Related]
18. Next generation sequencing for liquid biopsy based testing in non-small cell lung cancer in 2021.
Pisapia P; Costa JL; Pepe F; Russo G; Gragnano G; Russo A; Iaccarino A; de Miguel-Perez D; Serrano MJ; Denninghoff V; Quagliata L; Rolfo C; Malapelle U
Crit Rev Oncol Hematol; 2021 May; 161():103311. PubMed ID: 33781866
[TBL] [Abstract][Full Text] [Related]
19. Liquid Biopsy Versus Tissue Biopsy to Determine Front Line Therapy in Metastatic Non-Small Cell Lung Cancer (NSCLC).
Raez LE; Brice K; Dumais K; Lopez-Cohen A; Wietecha D; Izquierdo PA; Santos ES; Powery HW
Clin Lung Cancer; 2023 Mar; 24(2):120-129. PubMed ID: 36585341
[TBL] [Abstract][Full Text] [Related]
20. Traditional Diagnostics versus Disruptive Technology: The Role of the Pathologist in the Era of Liquid Biopsy.
Sholl LM; Oxnard GR; Paweletz CP
Cancer Res; 2020 Aug; 80(16):3197-3199. PubMed ID: 32606002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
